Trials and Research Search | SIU School of Medicine

Showing: 13 Results

Trial

Neurology

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

Trial

Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

Trial

Neurology

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Trial

Simmons Cancer Institute

ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

Active recruiting

This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of a

Trial

Simmons Cancer Institute

BC-IMT-04: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Active recruiting

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Trial

Simmons Cancer Institute

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk

Active recruiting

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

Trial

Obstetrics and Gynecology

Endometriosis and the Microbiome

Active recruiting

PURPOSE: Endometriosis is an inflammatory disorder in which the tissue that lines the inside of the uterus (the endometrium) spreads to the pelvic and peritoneal cavities outside of the uterus. This is a biological sample collection study examining how bacteria located within the vagina, the urogenital tract and the gastrointestinal tract may affect the development of endometriosis. Investigators are also exploring how an individual’s microbiome affects their estrogen metabolism and inflammation.

Trial

Neurology

Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Trial

Neurology

Supernus Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.

Clinical trials and research studies